Multiple clinical-stage biotechs unveil bold 2025 roadmaps—from Denali’s upcoming BLA for Hunter syndrome to Cabaletta’s expanding autoimmune cell …
Multiple clinical-stage biotechs unveil bold 2025 roadmaps—from Denali’s upcoming BLA for Hunter syndrome to Cabaletta’s expanding autoimmune cell …
Mereo BioPharma’s Phase 3 study in osteogenesis imperfecta progresses to interim analysis, while alvelestat gains momentum toward EU orphan …
A pivotal agreement between uniQure and the FDA ignites momentum for Huntington’s gene therapy, while Europe’s regulatory landscape …
CMS approval of Tempus’s AI-powered ECG‑AF algorithm marks its inclusion under U.S. Medicare reimbursement, enabling broader access to …
As 2024 wraps up, end-of-year research highlights—from AI-driven disease detection to expanded diagnoses and novel trial milestones—are shaping …
With generative AI powering personalized insights, Dexcom’s new Stelo CGM enters the market as the first FDA-cleared over-the-counter …
From decentralized designs to ethical reform, the NIH Pragmatic Trials Collaboratory closes 2024 with a blueprint for smarter, …
With its first-in-class mechanism and monthly dosing, Depemokimab sets a new benchmark in biologic treatment for high-burden asthma …
NIH-backed research reveals that a simple skin test may revolutionize early diagnosis of Parkinson’s and related neurodegenerative disorders.
The bispecific antibody earns full approval after demonstrating durable responses in heavily pre-treated patients.
Already a subscriber? Log in